Home/Pipeline/PTC518

PTC518

Huntington's disease

Phase 2Clinical

Key Facts

Indication
Huntington's disease
Phase
Phase 2
Status
Clinical
Company

About PTC Therapeutics

PTC Therapeutics is a patient-centric, publicly traded biopharma leader dedicated to translating groundbreaking science into life-changing treatments for rare diseases. Its key achievements include commercializing a series of 'firsts' in rare disease treatment and building a diversified pipeline targeting neurological and metabolic disorders. The company's strategic direction is fueled by its deep expertise in two core scientific platforms—splicing modifiers and inflammation/ferroptosis inhibitors—and a robust global commercial infrastructure to support its mission of delivering transformative medicines worldwide.

View full company profile

Other Huntington's disease Drugs

DrugCompanyPhase
SRP-1005 (ARO-HTT)Arrowhead PharmaceuticalsPhase 1
Undisclosed HD Program(s)WaVe Life SciencesPreclinical
AMT-130uniQurePhase 1/2
Undisclosed ProgramSangamo TherapeuticsPreclinical
Pepinemab (VX15/2503)VaccinexPhase 2